Insider Selling: Scholar Rock (NASDAQ:SRRK) Insider Sells 8,406 Shares of Stock

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Mo Qatanani sold 8,406 shares of the company’s stock in a transaction on Friday, January 16th. The stock was sold at an average price of $44.48, for a total value of $373,898.88. Following the transaction, the insider directly owned 100,558 shares in the company, valued at $4,472,819.84. This represents a 7.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Mo Qatanani also recently made the following trade(s):

• On Wednesday, January 14th, Mo Qatanani sold 13,112 shares of Scholar Rock stock. The shares were sold at an average price of $45.20, for a total value of $592,662.40.
• On Thursday, December 4th, Mo Qatanani sold 136,462 shares of Scholar Rock stock. The stock was sold at an average price of $45.21, for a total transaction of $6,169,447.02.

Scholar Rock Price Performance

Shares of SRRK traded up $1.31 during trading hours on Wednesday, reaching $46.05. The company had a trading volume of 1,173,163 shares, compared to its average volume of 836,796. The company has a current ratio of 6.30, a quick ratio of 6.30 and a debt-to-equity ratio of 0.41. Scholar Rock Holding Corporation has a 12-month low of $22.71 and a 12-month high of $48.28. The firm has a 50 day simple moving average of $43.23 and a 200-day simple moving average of $37.16. The company has a market capitalization of $4.70 billion, a price-to-earnings ratio of -14.62 and a beta of 0.63.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.90) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period in the previous year, the firm earned ($0.66) EPS. Research analysts expect that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current year.

Analysts Set New Price Targets

SRRK has been the subject of several research analyst reports. Wolfe Research assumed coverage on Scholar Rock in a research note on Tuesday, November 18th. They issued an “outperform” rating and a $42.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Scholar Rock in a report on Wednesday, October 8th. Barclays lifted their price target on Scholar Rock from $45.00 to $52.00 and gave the stock an “overweight” rating in a research note on Wednesday, December 17th. Truist Financial decreased their price objective on shares of Scholar Rock from $54.00 to $44.00 and set a “buy” rating on the stock in a research report on Monday, October 20th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a report on Thursday, December 11th. Four investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $50.14.

Institutional Investors Weigh In On Scholar Rock

Hedge funds and other institutional investors have recently modified their holdings of the company. Newbridge Financial Services Group Inc. purchased a new position in shares of Scholar Rock during the fourth quarter valued at approximately $132,000. StoneCrest Wealth Management Inc. raised its holdings in Scholar Rock by 24.7% in the 4th quarter. StoneCrest Wealth Management Inc. now owns 59,003 shares of the company’s stock valued at $2,494,000 after acquiring an additional 11,671 shares during the last quarter. Tema Etfs LLC lifted its stake in shares of Scholar Rock by 6.6% during the 4th quarter. Tema Etfs LLC now owns 9,899 shares of the company’s stock worth $436,000 after purchasing an additional 616 shares during the period. Three Seasons Wealth LLC boosted its holdings in shares of Scholar Rock by 2.1% during the fourth quarter. Three Seasons Wealth LLC now owns 10,968 shares of the company’s stock worth $483,000 after purchasing an additional 222 shares during the last quarter. Finally, SG Americas Securities LLC boosted its holdings in shares of Scholar Rock by 602.4% during the fourth quarter. SG Americas Securities LLC now owns 84,349 shares of the company’s stock worth $3,716,000 after purchasing an additional 72,341 shares during the last quarter. 91.08% of the stock is currently owned by hedge funds and other institutional investors.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).